⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARDX News
Ardelyx, Inc.
Form 8-K
sec.gov
ARDX
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
ARDX
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
globenewswire.com
ARDX
Ardelyx Receives New Patent for Tenapanor
globenewswire.com
ARDX
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
globenewswire.com
ARDX
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
prnewswire.com
ARDX
FATE
MNKD
VRTX
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
globenewswire.com
MNKD
VRTX
FATE
ARDX
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
globenewswire.com
ARDX
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
globenewswire.com
ARDX
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
globenewswire.com
ARDX